Mutant parasites for use as vaccines and platforms for screening for compounds
View Patent ↗Cloning and characterization of a TgIF2α kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2α kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2α phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2α mutant (S71A substitution) exhibited loss of eIF2α kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2α phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.
1. A method of identifying a compound, comprising the steps of: providing at least one translation initiation factor identified in a single celled eukaryotic parasite, wherein the translation initiation factor is phosphorylated by a TgIF2K-D kinase having at least 90% identity to SEQ ID NO: 13; contacting the TgIF2k-D kinase of SEQ ID NO: 13 with at least one compound; measuring the activity of the TgIF2K-D kinase of SEQ ID NO: 13 in the presence of the at least one compound; and identifying the at least one compound as an inhibitor of TgIF2K-D kinase of SEQ ID NO: 13 if the at least one compound reduces the activity of the TgIF2K-D kinase of SEQ ID NO: 13.
2. The method according to claim 1 , wherein the single celled parasite is selected from the group of genera consisting of Toxoplasma, Plasmodium and Cryptosporidium.